The monocyte activation test (MAT) has been introduced as an alternative for the detection of pyrogens in pharmaceuticals with the rabbit pyrogen test or the Limulus amebocyte lysate (LAL) test. The basis of the MAT is that pyrogens, via Toll-like receptors (TLRs) expressed on monocytes, stimulate cytokine production. Here, we report that, at concentrations that did not induce whole blood cytokine production when tested separately, (1→3)-β-D-glucans powerfully co-stimulated cytokine production (IL-6/IL-8) induced by ligands for TLR1/2, TLR2/6, TLR4, and TLR5. Experiments were performed to investigate the involvement of particular (1→3)-β-D-glucan receptors such as dectin-1. Spleen tyrosine kinase (Syk) inhibition attenuated the potentiating effects of (1→3)-β-D-glucans on TLR-induced cytokine production, suggesting that dectin-1 was involved. However, experiments with low molecular (1→3)-β-D-glucans such as laminarin argued against the involvement of dectin-1 in the co-stimulatory effects of (1→3)-β-D-glucans. Thus, although the receptors involved in the co-stimulatory actions of (1→3)-β-D-glucans on TLRinduced cytokine production are yet to be elucidated, it is clear that (1→3)-β-D-glucans may greatly affect MAT results and, when undetected in pharmaceuticals, may give rise to serious side-effects in patients co-exposed to other elicitors of innate immunity, such as during infections.
INTRODUCTION
To prevent detrimental side-effects of pharmaceutical therapy, the measurement of pyrogens is an important safety precaution for parenterally applied pharmaceuticals. The presence of pyrogens in pharmaceutical products has been conventionally tested with the rabbit pyrogen test 1 or the Limulus amebocyte lysate (LAL) test. 2 However, in addition to ethical and financial objections against the rabbit pyrogen test, considerable differ-ences between humans and rabbits in the response to particular pyrogens have been reported. 3 Even more importantly, some parenteral products have caused pyrogenic responses in patients even after passing the rabbit pyrogen test. 4, 5 The LAL-test for bacterial endotoxin does not detect other bacterial products, whether Grampositive or Gram-negative, and is susceptible to interference by high protein levels in test substances as well as by (1→3)-β-D-glucans, 6, 7 which are found in the cell walls of yeast, fungi, and some plant tissues. 8 The (1→3)-β-D-glucan-related interference was explained by the discovery of a (1→3)-β-D-glucan-mediated coagulation pathway in the Limulus hemolymph, which functions in addition to the endotoxin-mediated pathway. 9 In an effort to broaden the range of detectable pyrogenic substances, a number of different systems using peripheral blood mononuclear cells (MNCs), diluted whole blood, as well as monocytoid cell lines Mono Mac 6 10 and THP-1 11 as a source for human monocytes with various cytokine readouts have been established. 12 The basis of the in vitro pyrogen test, better referred to as monocyte activation test (MAT), is that pyrogens, via Toll-like receptors (TLRs) and other receptors, stimulate cytokine production in monocytoid cells. Endotoxins from Gram-negative bacteria and constituents of Gram-positive bacteria such as peptidoglycan, lipoteichoic acid, lipoproteins, and lipopeptides stimulate monocytes via TLRs and induce cytokine production. [13] [14] [15] Although much less studied, also components derived from yeast 16 and fungi 17 can stimulate cytokine production in human monocytes, probably via TLR2.
One of the absolute requirements for MAT systems is that all reagents used should be free of pyrogenic contamination. However, experience in our laboratory indicates that substances, which when tested separately are found to be free of stimulatory material, can still greatly increase cytokine production in co-operation with other stimuli (unpublished observations). Others also observed that aminoglycoside antibiotics, despite being free of cytokine-inducing contaminants, markedly augmented lipopolysaccharide (LPS)-induced cytokine production. 18 This raises the question whether pharmaceutical products should be tested for the presence of these 'immunomodulatory' substances.
Known immunomodulators are ligands for Nod1/Nod2 receptors. Nod2 ligands, such as muramyldipeptides, were demonstrated to potentiate TLR ligand-induced cytokine production in monocytic cells, 19 but little is known about the effects of Nod1 ligands on cytokine production. Other immunomodulators are (1→3)-β-Dglucans, a heterogeneous group of D-glucose polymers found in yeast, fungi, plants, and some bacteria, that have long been used as anti-infective and anti-tumor drugs due to their ability to trigger the production of reactive oxygen species, inflammatory mediators and cytokines, and the up-regulation of cellular cytotoxicity. 8, 20 Several (1→3)-β-D-glucan receptors, such as complement receptor 3 (CR3), 20 lactosylceramide and scavenger receptors, 8 and the serum protein L-ficolin, 21 have been implicated in these activities. However, most experimental data have indicated that the biological effects of (1→3)-β-D-glucans are mediated by the transmembrane receptor dectin-1. 8 Dectin-1 is involved in the recognition of (1→3)-β-D-glucans from the cell wall of fungi such as Candida albicans and Aspergillus fumigatus, and from the cell wall of yeasts such as Saccharomyces cerevisiae. 22, 23 Interestingly, Zymosan, a particulate β-glucan-rich extract derived from S. cerevisiae, is recognized by TLR2 in collaboration with dectin-1, 16 and stimulates TNF production in macrophages. 24 However, TLR2 does not appear to recognize purified (1→3)-β-D-glucan structures. 8 Also, no consensus has been reached on the capacity of purified fungal/yeast (1→3)-β-D-glucan structures to induce cytokine production, as both stimulatory [25] [26] [27] [28] and inhibitory [28] [29] [30] effects have been reported.
In the present study, we sought to investigate the powerful co-stimulatory effects of substances derived from cellulose dialysis membranes on TLR ligand-induced, whole blood cytokine production. Since we hypothesized that (1→3)-β-D-glucans leached from the cellulose dialysis membrane exerted these effects, we compared the cytokine production in response to low concentrations of TLR ligands in the presence of dialysis membrane extract, an extract from menstrual tampons rich in (1→3)-β-D-glucans, the (1→3)-β-D-glucan pachyman, as well as known immunomodulators such as ligands for Nod1/Nod2 receptors.
MATERIALS AND METHODS

Cells and cell cultures
Blood was obtained from healthy volunteers after informed consent in line with the Sanquin Ethical Advisory Council. Blood samples were collected from healthy volunteers using endotoxin-free evacuated blood collection tubes (Greiner, Alphen a/d Rijn, The Netherlands) containing sodium heparin. For whole blood cultures, venous blood was diluted 1/10 with Iscove's Modified Dulbecco's Medium (IMDM; Bio Whittaker, Verviers, Belgium) supplemented with 0.1% heat-inactivated fetal calf serum, 15 U/ml heparin (Leo Pharmaceutical Products, Weesp, The Netherlands), penicillin 100 U/ml, streptomycin 100 µg/ml, and 50 µM 2-mercaptoethanol. All experiments, except those in which LPS was used as a stimulus, were carried out in the presence of 10 µg/ml polymyxin-B. After 16-20 h of stimulation of whole blood cultures, supernatants were harvested for determination of cytokine production.
Human epithelial kidney 293 (HEK) cells stably transfected with CD14, CD14-TLR2 or CD14-TLR4 were a kind gift from Drs D. Golenbock and E. Latz (Worcester, MA, USA) and have been described elsewhere. 50 Transfected HEK cells were cultured in IMDM supplemented with 5% heat-inactivated fetal calf serum (FCS, Bodinco, Alkmaar, The Netherlands), penicillin 100 U/ml, streptomycin 100 µg/ml (Gibco, Merelbeke, Belgium), 50 µM 2-mercaptoethanol (Sigma-Aldrich, Steinheim, Germany), and 5 µg/ml puromycin (Sigma). For stimulation experiments, cells were seeded at 5 x 10 5 cells/well in 96-well, flat-bottom, microtitre plates (Nunc, Roskilde, Denmark) and stimulated the next day. HEK-CD14-TLR4 cells were stimulated in the presence of 5% human serum as described elsewhere (Kikkert et al., 2007, accepted for publication). After 16-20 h of stimulation, supernatants were harvested for determination of IL-8 production.
Both HEK cells and diluted whole blood were cultured in 200 µl wells at 37°C in the presence of 5% CO 2 , in a humidified incubator.
Drugs and stimuli
Regenerated cellulose dialysis membranes (dialysis tubing Visking) were from Roth, Karlsruhe, Germany. Dialysis extract was prepared by boiling 100 cm 2 of dialysis membranes in 50 ml saline for 30 min. Pachyman isolated from Poria cocos as described 37 and menstrual tampon extract were from the research department of Associates of Cape Cod (East Falmouth, MA, USA). A monoclonal antibody raised against human dectin-1 (GE2) 40 was a generous gift from Dr G. Brown (Cape Town, South Africa). Glucan phosphate was kindly provided by Dr D.L. Williams (Johnson City, TN, USA) and has previously been described. 39 Neutralizing monoclonal antibodies raised against CD11b (44A) and CD18 (1B4) were a kind gift of Dr D. Roos, this institute, and have been described elsewhere. 51 FK156 and FK565 were kindly provided by Astellas Pharma Inc., Osaka, Japan and have been previously described. 41 Escherichia coli LPS serotype O55:B5, laminarin, Staphylococcus aureus lipoteichoic acid (LTA), and polymyxin-B were from Sigma. Staphylococcus aureus Cowan I cells (SAC; Pansorbin) and Syk inhibitor III (3,4-methylenedioxy-β-nitrostyrene) were from Calbiochem (San Diego, CA, USA). A synthetic muramyldipeptide (MDP) and its inactive stereoisomer, N-acetylmuramyl-L-aranyl-Lisoglutamine (MDP-LL) were purchased from InvivoGen (San Diego, CA, USA). S. aureus peptidoglycan and Salmonella typhimurium flagellin were also from InvivoGen. Polyriboinosinic polyribocytidylic acid (poly I/C) was from Pharmacia Biotech (Piscataway, NJ, USA), and FSL-1 (fibroblast-stimulating lipopeptide) and PAM-3 (Pam 3 Cys-S-KKKK x HCl) were from EMC Microcollections (Tuebingen, Germany).
Cytokine measurements
IL-6 and IL-8 were determined by ELISA kits (Peli-Kinecompact, Sanquin Reagents, Amsterdam, The Netherlands), according to the manufacturer's instructions. The plates were read in an ELISA-reader (Labsystems Multiskan Multisoft, Helsinki, Finland) at 450 nm, with 540 nm as a reference.
RESULTS
In the course of experiments performed to evaluate the effect of a recombinant protein (IL-6), expressed in Pichia pastoris, on cytokine production, we noted that recombinant IL-6 potentiated LPS-or S. aureus Cowan 1 (SAC) cell-induced IL-8 production in diluted whole blood. The co-stimulatory effect of the recombinant IL-6 was absent when it was directly added from P. pastoris cultures to whole blood cultures, but became apparent after dialysis of the protein against phosphate buffered saline (PBS). Subsequent experiments revealed that PBS itself, after dialysis, potentiated LPS-or SAC-induced IL-8 production (not shown). This raised the possibility that so-called immunomodulatory mediators, possibly (1→3)-β-D-glucans, leached from the cellulose dialysis membranes and potentiated LPS/SAC-induced cytokine production. To investigate this, we prepared a dialysis membrane extract (see Materials and Methods) and compared its effects with those of known immunomodulators such as FK156/FK565 and muramyldipeptide (MDP) on Toll-like receptor (TLR)-induced cytokine production.
IL-6 and IL-8 production were increased 2-or 3-fold after stimulation of whole blood with a combination of LPS and Nod1 ligands (FK156 or FK565) compared to stimulation with LPS alone (Fig. 1) . Also, the Nod2 lig- and MDP moderately potentiated LPS-induced IL-8 production (not shown). The extract prepared from cellulose dialysis membranes failed to stimulate whole blood IL-8 ( Fig. 2A) or IL-6 production ( Fig. 2B ) when tested separately, but powerfully enhanced (3-15-fold) SACinduced IL-8 and IL-6 production. Also, whole blood cytokine production induced by other TLR ligands such as lipoteichoic acid, PAM-3, FSL-1, peptidoglycan (all TLR2), LPS (TLR4), and flagellin (TLR5) was markedly potentiated by the dialysis membrane extract (not shown). Since a large body of evidence indicates that (1→3)-β-D-glucans may leach from other cellulose membranes and filters [31] [32] [33] [34] [35] and because cotton medical devices, such as medical gauze sponges, packings, and tampons were observed to very rapidly leach large quantities of (1→3)-β-D-glucans into normal saline, 36 we tested a (1→3)-β-D-glucan-rich extract prepared from menstrual tampons for its potency to co-stimulate SAC-induced cytokine production. Again, both SAC and tampon extract only moderately stimulated IL-8 production when tested separately, whereas the combination of SAC and tampon extract synergistically induced IL-8 production ( Fig. 3 ). Since these data strongly suggested that (1→3)-β-D-glucans were responsible for the co-stimulatory effects observed, we continued our experiments with a purified (1→3)-β-D-glucan, pachyman, an almost linear (1→3)β-D-glucan with only minor β-(1→6) glucosidic sidechains, similar in structure to curdlan, 37 for its potency to co-stimulate TLR ligand-induced cytokine production.
Like dialysis membrane extract and tampon extract, pachyman markedly potentiated IL-8 ( Fig. 4A ) and IL-6 ( Fig. 4B ) production induced by SAC. To illustrate this, in conditions where pachyman and SAC separately induced only minor IL-8 production (0.41 ± 0.05 ng/ml and 0.23 ± 0.04 ng/ml, respectively), we tested the combination of pachyman and SAC. This combination induced much higher levels of IL-8 (9.0 ± 0.7 ng/ml; Fig. 4C ). Pachyman, by itself, also dose-dependently induced some IL-8 production (Fig. 4A ). However, as we were interested in the possible co-stimulatory effects of low levels of (1→3)-β-D-glucan contamination in test substances for the MAT, we chose a concentration of pachyman (0.25 µg/ml) that only minimally stimulated IL-8 production for subsequent experiments.
The effect of pachyman on cytokine production induced by other TLR ligands was also studied. Whole blood was stimulated with FSL-1 (TLR2/6), PAM-3 (TLR1/2), flagellin (TLR5; Fig. 5A ) or LPS (TLR4; Fig.  5B ) at low concentrations that only induced moderate IL-8 production when tested separately. Again, stimulation of whole blood with both TLR ligands and pachyman markedly potentiated IL-8 production compared to the separate stimuli ( Fig. 5A, B) . Also IL-6 production induced by FSL-1, PAM-3, flagellin, and LPS was potentiated by pachyman, albeit to a much smaller extent than IL-8 production ( Fig. 5C, D) . Pachyman only slightly increased IL-8 production induced by poly I/C, a ligand for TLR3 ( Fig. 5A ).
Next, we investigated whether the potentiating effect of (1→3)-β-D-glucans on TLR ligand-induced cytokine production was mediated by dectin-1. Since dectin-1-mediated activation of cells could be prevented, at least partially, by inhibition of spleen tyrosine kinase (Syk), 22, 38 we also tested whether Syk inhibition suppressed the co-stimulatory effects of pachyman on cytokine production. Pachyman and FSL-1 induced minimal IL-8 production when tested alone, whereas the combined use of pachyman and FSL-1 led to a vigorous IL-8 response (Fig. 6A ). Syk inhibition partially suppressed the co-stimulatory effect of pachyman on FSL-1-induced IL-8 production (Fig. 6B) . Also, the costimulatory effect of pachyman on SAC-induced IL-8 production was partially inhibited by Syk kinase inhibition, whereas the IL-8 production induced by SAC alone was unaffected (Fig. 6C) .
To investigate the involvement of dectin-1 further, we tested whether low molecular mass (1→3)-β-D-glucans, such as laminarin and glucan phosphate, were capable of inhibiting the co-stimulatory effects of pachyman on TLR ligand-induced cytokine production. At a concentration of 100 µg/ml, laminarin alone did not induce IL-8 production and failed to inhibit the co-stimulatory effect of dialysis extract (not shown) and pachyman on SAC-induced IL-8 production (Fig. 7A ). However, laminarin partially inhibited IL-8 production when whole blood was stimulated with higher concentrations of pachyman (> 1 µg/ml; Fig. 7B ), whereas IL-6 production was completely abrogated ( Fig. 7C ). Finally, glucan phosphate 39 as well as monoclonal antibodies raised against human dectin-1, 40 CD11b, or CD18, failed to inhibit cytokine production induced by either pachyman alone or by pachyman together with a TLR stimulus (data not shown).
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DISCUSSION
In keeping with the results obtained by others, 41 we found that LPS-induced cytokine production was moderately potentiated by Nod1 ligands FK156 and FK565, as well as by the Nod2 ligand MDP. In contrast with the moderate effects of these immunomodulators on LPSinduced cytokine production, dialysis membrane extract vigorously potentiated TLR-induced cytokine production. Because our dialysis extract was ill-defined and a body of evidence indicated that regenerated cellulose membranes, such as dialysis membranes, leach (1→3)β-D-glucans, [31] [32] [33] [34] [35] we hypothesized that (1→3)-β-D-glucans were responsible for the co-stimulatory effects observed. Therefore, we continued our experiments with a (1→3)-β-D-glucan-rich extract from menstrual tampons and a purified (1→3)-β-D-glucan, pachyman, 37 that is used as (1→3)-β-D-glucan standard in an alternative LAL assay (Fungitell ® ; Associates of Cape Cod, East Falmouth, MA, USA) which specifically measures (1→3)β-D-glucans. 35 At concentrations as low as 0.25 µg/ml, pachyman markedly co-stimulated IL-8 production induced by ligands for TLRs expressed on monocytes and/or neutrophils, such as TLR1/2, TLR2/6, TLR4 and TLR5. It should be noted that, in these experiments, stimulation with TLR ligands (other than LPS) was carried out in the presence of polymyxin-B, a polycationic compound that specifically inhibits LPS, and which, at 10 µg/ml, is able to neutralize at least 1 ng/ml E. coli LPS in whole blood assays. Therefore, we assume that the potentiating effects of pachyman on TLR ligand-induced cytokine production are exerted by the (1→3)-β-D-glucan structure itself, and not by possible endotoxin contamination. In support of this, pachyman did not stimulate HEK cells stably transfected with CD14/TLR2 or CD14/TLR4 (data not shown), which also indicates that the moderate stimulation of cytokine production in whole blood induced by pachyman is caused by the (1→3)-β-D-glucan itself. Also, others 26, 27 demonstrated co-stimulatory effects of (1→3)-β-D-glucans on cytokine production. In these studies, high concentrations of LPS (0.1-10 µg/ml; 26 0.5-50 ng/ml 27 ) and (1→3)-β-D-glucans (50-500 µg/ml; 26 2-20 µg/ml 27 ) were used, and only moderate increases in cytokine production (3-4-fold) were recorded. Thus, these studies reported that (1→3)-β-Dglucans increase the maximum response to LPS only, whereas our study demonstrates that low concentrations of the (1→3)-β-D-glucan pachyman (0.25 µg/ml) exert a powerful effect on cytokine production induced by low concentrations of multiple TLR ligands.
As a matter of course, we sought to investigate which receptors on monocytes and/or neutrophils were involved in the co-stimulatory effects of pachyman on TLR-induced cytokine production. Recently, it was demonstrated that activation of cells via dectin-1, the major human receptor for (1→3)-β-D-glucans, 8, 42 could be prevented by inhibition of the tyrosine kinase Syk. 22, 38 Also the potentiating effects of pachyman on FSL-1-and SAC-induced cytokine production were partially inhibited by Syk inhibition, whereas the response to SAC was unaffected. However, caution should be exercised when interpreting data on blood cells and enzyme inhibitors, because of the frequently observed non-specific and toxic effects of these inhibitors on blood cells. Hence, we attempted other methods of inhibiting dectin-1. Previous studies have indicated that low molecular mass (1→3)-β-D-glucans, such as laminarin or glucan phosphate, inhibited the dectin-1-mediated phagocytosis of (1→3)-β-D-glucan-rich zymosan. 16, 40, 42, 43 However, both laminarin and glucan phosphate failed to inhibit the costimulatory effect of pachyman on TLR-induced cytokine production, suggesting that the co-stimulatory actions of pachyman may be mediated by (1→3)-β-Dglucan receptors different from dectin-1. Because we found that high concentrations of pachyman (> 1 µg/ml) stimulated cytokine production without the requirement of a TLR stimulus, we sought to inhibit cytokine production induced by pachyman alone with these low molecular mass (1→3)-β-D-glucans. Although glucan phosphate was ineffective in this regard, laminarin partially inhibited pachyman-induced IL-8 production and completely abrogated pachyman-induced IL-6 production. Since neutrophils are incapable of synthesizing IL-6, 44 this suggested that a particular (1→3)-β-D-glucan receptor expressed on monocytes, possibly dectin-1, is preferentially inhibited by laminarin. Due to alternative splicing, human dectin-1 is expressed as two major isoforms. 43 The A isoform contains a stalk region and is expressed exclusively on neutrophils, whereas the B isoform lacks the stalk region and is expressed both on neutrophils and monocytes. 43 Therefore, we surmise that laminarin blocks the B isoform of dectin-1, which would explain the partial inhibition of IL-8, and the complete inhibition of IL-6 production induced by pachyman. Finally, a monoclonal antibody raised against dectin-1 failed to inhibit cytokine production induced by pachyman alone or induced by pachyman together with a TLR stimulus. This indicates that this monoclonal antibody, despite blocking dectin-1-mediated phagocytosis of zymosan, 40 is not capable of preventing dectin-1-mediated cytokine production or, alternatively, that dectin-1 is not involved in the co-stimulatory actions of pachyman on TLRinduced cytokine production. As glucan phosphate, laminarin, and the anti-dectin-1 monoclonal antibody did not inhibit the co-stimulatory effects of pachyman on TLR-induced cytokine production, we hypothesize that (1→3)-β-D-glucan receptors different from dectin-1 are involved in the co-stimulation of TLR-induced cytokine production by low concentrations (0.25 µg/ml) of pachyman. However, at higher concentrations (> 1 µg/ml) of pachyman, dectin-1 may also become activated and play, independent of TLR activation, a role in the activation of monocytes and neutrophils resulting in cytokine production. It is clear that further studies on the potentiation by (1→3)-β-D-glucans of TLR-induced cytokine production are warranted. A recent review illustrates the influence of β-glucan molecular mass, (1→4) and/or (1→6) branching frequency, and physical state (soluble versus insoluble) on the biological activity of (1→3)-β-D-glucans. 45 The complex nature of (1→3)-β-D-glucan parameters, as well as the role of several (monocyte) receptors in the co-stimulation by (1→3)-β-D-glucans of TLR-induced cytokine production, should be investigated in future experiments.
When pharmaceuticals for parenteral use are tested in vitro for the presence of pyrogens, the common assumption is made that a 'pass' result implies that the drug is safe for use in humans. However, the MAT is performed in optimal and strictly controlled pyrogen-free conditions, whereas humans taking the same drug are exposed to multiple influences, including (sub)clinical viral or bacterial infections and drugs (e.g. antibiotics, NSAIDs). In this study, we have demonstrated that (1→3)-β-D-glucans can play a pivotal role in the magnitude of cytokine production after TLR stimulation. Therefore, it is clear that in vitro assays to test the pyrogenicity of pharmaceuticals should take this effect of (1→3)-β-D-glucans into consideration. To illustrate this, recent data demonstrated that some pharmaceuticals such as vaccine allergens 46 and intravenous antibiotics 47, 48 contain (1→3)-β-D-glucans, which may explain how antibiotics enhanced the endotoxin activity as observed by others. 18 In addition, harmful interactions between NSAIDs and (1→3)-β-D-glucans were demonstrated in mice 49 which may exist in humans as well. Therefore, we consider it reasonable to test pharmaceuticals for the presence of (1→3)-β-D-glucans. For this purpose a (1→3)-β-D-glucan-specific LAL assay may be employed. 35 Alternatively, pharmaceuticals may be tested in the MAT in the presence of low concentrations of TLR ligands which alone do not stimulate cytokine production, but, in synergy with (1→3)-β-D-glucan contamination, greatly increase cytokine production, thereby exposing possible (1→3)-β-D-glucan contamination of pharmaceuticals.
